Stevens Capital Management LP Has $355,000 Stock Holdings in DaVita Inc. (NYSE:DVA)

Stevens Capital Management LP cut its stake in DaVita Inc. (NYSE:DVA) by 17.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 3,392 shares of the company’s stock after selling 698 shares during the quarter. Stevens Capital Management LP’s holdings in DaVita were worth $355,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of DVA. PNC Financial Services Group Inc. boosted its holdings in DaVita by 1.0% in the third quarter. PNC Financial Services Group Inc. now owns 15,088 shares of the company’s stock worth $1,426,000 after purchasing an additional 153 shares in the last quarter. Kingswood Wealth Advisors LLC bought a new stake in DaVita during the fourth quarter valued at about $2,831,000. Raymond James & Associates boosted its holdings in DaVita by 135.2% during the fourth quarter. Raymond James & Associates now owns 34,376 shares of the company’s stock valued at $3,601,000 after acquiring an additional 19,759 shares during the period. Nisa Investment Advisors LLC boosted its holdings in DaVita by 27.8% during the fourth quarter. Nisa Investment Advisors LLC now owns 50,981 shares of the company’s stock valued at $5,341,000 after acquiring an additional 11,097 shares during the period. Finally, Assenagon Asset Management S.A. boosted its holdings in DaVita by 2,178.2% during the fourth quarter. Assenagon Asset Management S.A. now owns 108,624 shares of the company’s stock valued at $11,379,000 after acquiring an additional 103,856 shares during the period. 90.12% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. StockNews.com upgraded shares of DaVita from a “buy” rating to a “strong-buy” rating in a report on Thursday. Barclays started coverage on shares of DaVita in a research report on Wednesday, March 6th. They set an “equal weight” rating and a $133.00 price objective for the company. Truist Financial increased their price target on shares of DaVita from $130.00 to $135.00 and gave the stock a “hold” rating in a research report on Tuesday, February 20th. UBS Group raised their price objective on shares of DaVita from $113.00 to $134.00 and gave the stock a “buy” rating in a report on Wednesday, February 14th. Finally, TheStreet raised shares of DaVita from a “c+” rating to a “b-” rating in a research note on Wednesday, February 7th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $118.50.

DaVita Trading Up 0.5 %

DVA stock traded up $0.73 during midday trading on Friday, reaching $133.50. The company’s stock had a trading volume of 477,665 shares, compared to its average volume of 798,575. DaVita Inc. has a 52 week low of $71.51 and a 52 week high of $141.54. The stock has a market cap of $11.71 billion, a PE ratio of 17.94, a price-to-earnings-growth ratio of 1.18 and a beta of 1.04. The company has a quick ratio of 1.13, a current ratio of 1.19 and a debt-to-equity ratio of 6.65. The business’s 50-day simple moving average is $131.89 and its 200-day simple moving average is $110.16.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Tuesday, February 13th. The company reported $1.87 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.53 by $0.34. DaVita had a net margin of 5.70% and a return on equity of 64.42%. The firm had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.01 billion. During the same period last year, the firm earned $1.11 earnings per share. The business’s revenue for the quarter was up 7.8% on a year-over-year basis. As a group, sell-side analysts expect that DaVita Inc. will post 9.23 EPS for the current year.

Insider Buying and Selling at DaVita

In related news, CEO Javier Rodriguez sold 67,603 shares of the firm’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $126.11, for a total transaction of $8,525,414.33. Following the sale, the chief executive officer now directly owns 488,697 shares in the company, valued at $61,629,578.67. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other DaVita news, CEO Javier Rodriguez sold 67,603 shares of DaVita stock in a transaction on Monday, February 26th. The shares were sold at an average price of $126.11, for a total value of $8,525,414.33. Following the sale, the chief executive officer now directly owns 488,697 shares in the company, valued at approximately $61,629,578.67. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael David Staffieri sold 29,488 shares of DaVita stock in a transaction dated Wednesday, February 21st. The shares were sold at an average price of $119.81, for a total transaction of $3,532,957.28. Following the completion of the transaction, the chief operating officer now directly owns 37,687 shares of the company’s stock, valued at approximately $4,515,279.47. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 134,540 shares of company stock valued at $16,551,071. 1.40% of the stock is currently owned by insiders.

DaVita Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.